[医药制造业] [2021-10-24]
10 月15 日,国务院医改领导小组印发《关于深入推广福建省三明市经验深化医药卫生体制改革的实施意见》。文件紧密围绕医疗联合体建设,从药耗集采、医疗服务价格调整、医务人员薪酬制度改革、医保支付方式改革等领域提出实施意见。
[医药制造业] [2021-10-24]
产品升级、国产替代。制药上游装备/试剂公司处在产业升级的关键节点,2020-2021年全球新冠疫情中,部分国产制药装备、科研试剂公司把握了需求快速增长&升级的窗口期,缩小与海外公司差距。后疫情阶段,我们认为国产替代、需求升级(新技术、新市场)驱动上游装备/试剂公司产品升级“长牛”空间。
[医药制造业] [2021-10-24]
中国疫苗产业通过新冠疫情防控从资金实力、国内疫苗产业链配套、人才队伍和国际化等方面得到全面提升。同时疫情后时代国内疫苗企业也将迎来进一步分化。
[医药制造业] [2021-10-24]
Women’s health makes only 4% of the overall funding that goes into the research and development of healthcare products and services. Most of the spending on diseases is male-specific. Male-specific conditions such as prostate cancer account for around 2% of the overall funding. Today, women account for 49.6% of the total population across the world. The economic burden on women-specific diseases has reached over $500 billion. Healthcare should become personalized and patient-centric, which, in turn, increases the demand for management and delivery of healthcare to be genderneutral. For several decades, healthcare products and solutions were designed, developed, and delivered without much attention to the fact that healthcare needs are different for men and women, considering their physiological differences. There is an urgent need for building different products for women and find solutions that are specific to the physiology of women. As there are fundamental differences in the process of metabolizing drugs for women and men, inclusion of women in product development, clinical trials, research, and marketing has become essential. Currently, a wave of change has emerged in healthcare companies that are increasingly recognizing the need to serve women better.
[医药制造业,仪器仪表制造业,计算机、通信和其他电子设备制造业] [2021-10-24]
The global AI in operating room market is in the initial stages with significant potential for growth during the forecast period, 2021-2030. The current market landscape involves hardware and software solutions that are deployed in operating rooms with AI and computer vision technology supporting the surgical teams to improve the output with added safety. The current barriers for conventional operations include factors such as lack of resources, training, languages, staff turnover, and the available skill level. AI solutions deployed in the operating room can stay up to date with surgical events and cross-check them with a large database of information. Thus, it can aid the surgical team in planning the next steps and predict outcomes. There are other types of algorithms that perform other functions, such as operating room management, scheduling, and tracking.
[医药制造业] [2021-10-24]
Artificial tears drug is used for the treatment of dry eye syndrome and allergic conjunctivitis. OTC artificial tears help to maintain moisture and well-being mostly in geriatric patients, who are vulnerable to dry eye syndrome due to intake of many medications and dysfunctions of lacrimal gland. This study comprises products only and not the services. The study estimates the revenue generated from the sales of OTC artificial tears. The valuations comprise revenue generated from adoption of OTC artificial tears by patients. The study scope focuses on OTC artificial drugs for hospital pharmacies, drug stores, and online pharmacies.
[医药制造业] [2021-10-22]
2021 年10 月18 日,百普赛斯于创业板上市,生物试剂行业迎来新标 的。作为生物试剂重组蛋白细分龙头,如何看待行业的整体空间、公司 的成长路径及当前龙头公司的发展是本篇报告主要聚焦的方向。
[医药制造业] [2021-10-22]
ESMO 2021 年会落幕,国产创新药研究受到国际认可。欧洲肿瘤内科 学会(ESMO)2021 年年会于9 月16 日至21 日在线上召开,本届大 会又迎来众多新数据披露。20 家国内创新药企通过口头汇报或Poster 的形式,发布了75 项重点研究结果。
[医药制造业] [2021-10-21]
[医药制造业] [2021-10-18]
Fertility test is the process of assessing both male and female for fertility issues and also to find the “fertile window” in the menstrual cycle of the women. The report provides market dynamics and trends related to the global fertility test market. In addition, it presents the estimations and forecast of the market. The study estimates the revenue generated from the sales of fertility test products. We have considered company profiles for ovulation prediction kits, fertility monitors, and male fertility testing products. The valuations comprise revenue generated from fertility test products such as ovulation prediction kits, fertility monitors, and male fertility testing products. Furthermore, the report excludes revenue generated from post-sale services of fertility test products.